INTRODUCTION
Early primary percutaneous coronary intervention (PPCI) is the preferred treatment for patients presenting with ST-elevation myocardial infarction (STEMI). Despite the improvement in both morbidity and mortality in these patients, groups at high risk of complications and adverse clinical events remain. Patients at high risk could potentially benefit from additional mechanical and pharmacological measures taken during and after PPCI. The ability to differentiate between patients at high and low risk may be a valuable tool to optimize the use of adjunctive therapies, which may improve outcomes.
Several demographic, electrocardiographic, and PCI-related characteristics have been identified as important prognostic factors regarding mortality in patients presenting with STEMI 1 . Furthermore, novel biomarkers such as N-terminal pro-brain natriuretic peptide (NT-pro-BNP) 2 , glucose 3 , C-reactive protein (CRP) 4 , creatinine or estimated glomerular filtration rate (eGFR) 5 , and cardiac troponin T (cTNT) 6 have been reported to be associated with an increased risk for mortality in STEMI patients. These biomarkers reflect left ventricular dysfunction, glucose metabolism, inflammation status, renal function, and myocardial cell damage, respectively.
Consequently, a multimarker approach may yield valuable prognostic information for STEMI patients undergoing PPCI and a simple multimarker risk score would be of particular value for fast, early assessment of baseline risk.
We investigated whether multiple biomarkers, either alone or in combination with established risk factors, improve prognostication in STEMI patients who underwent PPCI using a large database from a high-volume PCI center in The Netherlands.
METHODS

Source population and procedures
We used data from consecutive STEMI patients who underwent PPCI in our center between January 1, 2005 and January 5, 2007. The PPCI and adjunctive pharmacological treatment was performed according to the American College of Cardiology/American Heart Association and European Society of Cardiology guidelines. In general, patients were eligible for PPCI if they presented with ischemic chest pain, onset of symptoms no later than 12 hours, and at least 1 mm of ST-elevation in two contiguous leads on the 12-lead electrocardiogram. Patients received aspirin (500 mg), clopidogrel (300-600 mg), and unfractioned heparin (5000 IU). Glycoprotein IIb/IIIa inhibitors were used at the discretion of the operator. If a coronary stent was implanted, clopidogrel was prescribed for ≥1 month to patients with a bare-metal stent and for ≥6 months following a dug-eluting stent.
Biomarkers
Blood samples prior to PPCI were obtained as part of routine clinical care. Blood samples were drawn immediately after insertion of the arterial sheath prior to PPCI for assessment of cTnT, CRP, glucose, NT-pro-BNP, and plasma creatinine.
Blood samples were centrifuged without undue delay and analyzed. Both cTnT and NT-pro-BNP were measured using a Hitachi modular E-170 analyzer (Roche Diagnostics GmbH, Mannheim, Germany). CRP was measured with an immunoturbidimetric assay on a Hitachi modular P-800 (Roche Diagnostics GmbH). Glucose and plasma kreatinine was measured with an enzymatic assay on a Hitachi modular P-800 analyzer (Roche Diagnostics GmbH). The eGFR was calculated according to the Cockcroft and Gault formula 7 .
Data collection
Our local catheterization laboratory database was consulted for information about patients' demographics, procedural and angiographic characteristics that had been prospectively collected and entered by interventional cardiologists and specialized nurses. Patients were surveyed at 1 year after PPCI using a mailed questionnaire.
Study population
For the current analysis, we included all STEMI patients who underwent PPCI between January 1, 2005 and January 5, 2007 and had complete and valid laboratory measurements prior to PCI. Only the first PPCI was included in case of a patient with multiple PPCIs within the time window. We excluded STEMI patients presenting with cardiogenic shock (n=85) and patients undergoing rescue PCI after failed thrombolysis (n=10) 8 .
Outcomes
The outcome for our current analysis was all-cause mortality before November 6, 2008. Information on vital status obtained from the institutional database was synchronized with the Dutch national population registry and was verified until November 6, 2008.
Statistical analysis
Normal-distributed continues variables were compared with the Student T-test, skewed-distributed with the Wilcoxon rank-sum test. Categorical variables were compared with the chi-square test. The prognostic value of the biomarkers was assessed by investigating the relation between mortality and biomarkers in two sets of Cox proportional-hazards analyses: univariable analyses of single biomarkers and multivariable analysis including all biomarkers (multimarker). The univariable analyses were used to determine cut-off values for the biomarkers. These cut-off values were based on the quartiles of the individual biomarker levels. When hazard did not differ significantly between adjacent quartiles, as indicated by the P value from the Cox model, these were merged. A multivariable model was initially developed incorporating the five biomarkers. Biomarkers with a P<0.05 by the Wald test were identified by backwards selection. From the final model, a simplified score was obtained by putting weights to individual biomarkers proportional to the HR coefficients. The multimarker risk score was defined as the sum of these points, with higher points indicating a higher
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MULTIPLE BIOMARKERS IN STEMI mortality risk. Cut-offs for low-, intermediate-, and high-risk groups were determined according to thirds of risk among those who died. Cumulative event rates were estimated with the Kaplan-Meier method and compared with the log-rank test.
The additional prognostic value of the biomarkers in the multimarker risk score to established prognostic factors was assessed in a multivariable Cox proportionalhazards model. This model included the following established prognostic factors derived from the TIMI score: age, body mass index, history of diabetes or hypertension, systolic blood pressure and heart rate, anterior myocardial infarction, and time to treatment (symptom onset to first balloon inflation) 1, 9 . The increased discriminative value after addition of the biomarkers to the established prognostic factors was estimated using three measures: the Harrell's C index, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). The Harrell's C index is defined as the proportion of usable patients pairs in which the predictions and outcomes are concordant 10 The NRI and IDI were calculated by analyzing the differences in patients' individual estimated probability of mortality after addition of a single or multiple biomarkers to a model containing the aforementioned established prognostic factors 11 . As no a prior risk categories exist for two-year mortality, we chose Harrell's implementation of the NRI, where the combination of any improved and worsened probability results in the categoryless NRI ( Figure 1 ). Thus the reported NRI relatively indicates how many patients improve their predicted probability for mortality. The IDI considers the change in the estimated prediction probabilities as a continuous variable, and represents the average improvement in predicted probability. The NRI and IDI were calculated in patients with complete follow-up at two years.
The proportional-hazards assumptions of all analyses were assessed with Schoenfeld's tests, no relevant violations were observed.
RESULTS
A total of 1340 consecutive STEMI patients underwent PPCI at our institution between January 1, 2005 and January 5, 2007. We excluded 306 patients because of missing or incomplete biomarkers. The baseline characteristics of the 1034 included patients who had complete and valid biomarker measurements are shown in table 1. The mean age in our study population was 62 years, and 73% percent was male. The baseline characteristics of the included and excluded patients were comparable. There were clinically small, but statistically significant, differences in hypercholesterolemia, history of coronary artery bypass grafting (CABG), time to treatment and prevalence of anterior myocardial infarction. During a median follow-up time of 901 days (interquartile range 758 to 1122 days), 120 patients died (cumulative event rate 14.1%). All patients were identified in the national population registry.
Univariable analyses
In the univariable analyses, death rates significantly increased with increasing levels of the biomarkers cTnT, CRP, glucose, NT-pro-BNP, and eGFR ( 
Multimarker score
The multivariable analyses are shown in Table 3 . cTnT and CRP were not associated with an increased mortality, and were excluded from the final model. Within the final model, an eGFR <90 ml/min, NT-pro-BNP ≥150 ng/l, and a glucose ≥8 mmol/l were all associated with significant higher mortality hazards (P<0.05 for all). Based on the HR coefficients of the final multivariable model (Table 3) , a glucose 8-9 mmol/l, NTpro-BNP 150-600 ng/l, and eGFR 60-89ml/min were assigned 2 points, a glucose ≥10 mmol/l, and NT-pro-BNP ≥600 ng/l were assigned 3 points, and an eGFR <60 ml/min was assigned 4 points. The multimarker risk score is shown in Table 4 . The Kaplan-Meier curves of the low-risk (multimarker score ≤4), intermediate-risk (multimarker score 5 or 6), and the high-risk group (multimarker score >6) are shown in Figure 2 . Higher mortality at the end of follow-up was observed in the high-risk group (42.0%), when compared to the intermediate-risk (20.3%), or low-risk group (5.8%) (log-rank test for all pair wise comparisons P<0.001). 
Biomarkers and established prognostic factors
After adjustment for established risk factors, eGFR and NT-pro-BNP remained significant predictors for mortality, while a trend to higher mortality was observed with higher glucose values (Table 3 ). An eGFR <60 ml/min was associated with a 3.57 increased mortality hazard (HR 3.57, 95% CI: 1.57-8.11, P<0.01). A glucose of ≥10 mmol/l (HR 1.48, 95% CI: 0.83-2.64, P=0.19) was associated with a trend to higher mortality at the end of follow-up. Finally, a two-fold increase in mortality was observed with NT-pro-BNP values ≥600 ng/l (P<0.01). Adding eGFR, NT-pro-BNP, and glucose to the established risk factors improved the prediction of mortality, as shown by the increase in the Harrell's C index ( patients who died or were alive at follow up is presented by the NRI. Addition of each single biomarker (except glucose) or the three markers from our score significantly improved the reclassification of patients (P<0.001). The integrated discrimination significantly improved after addition of NT-pro-BNP, eGFR, or the three markers. Because we hypothesized that the relationship between admission glucose levels and mortality differed between diabetics and non-diabetics, we assessed the interaction between glucose and diabetes by testing the significance of this relation in the Cox proportional-hazards model with established risk factors. No interaction was observed (P=0.85).
DISCUSSION
Several inferences can be drawn from the current report. First, within multivariable analyses, glucose, NT-pro-BNP, and eGFR were the strongest predicting biomarkers of mortality. In contrast, cTnT and CRP were not predictive in the multivariable analysis. Incorporation of the three predictive biomarkers in the multimarker risk score yields important information regarding baseline risk and mortality. Importantly, as can be seen from Figure 2 , the increased mortality occurs early, and additional therapies to improve outcome should start as early as possible, preferably already during or immediately following PPCI. Finally, in our realworld cohort of STEMI patients undergoing PPCI, the addition of eGFR, NT-pro-BNP, and glucose to a model including established prognostic factors provided incremental prognostic information regarding mortality. This improvement was indicated statistically significant by the increase in the NRI and IDI.
Previous multimarker studies
To our best knowledge, this is one of the first studies to evaluate a multimarker approach for the prediction of baseline risk of long-term death in patients undergoing PPCI for STEMI. In another study of 298 patients receiving revascularization or thrombolysis for MI, a multimarker approach with NT-pro-BNP, CRP, matrix metalloproteinase-9, pregnancy-associated plasma protein A, myeloperoxidase, soluble CD40 ligand, and fibrin monomer rendered no additional prognostic information beyond conventional risk stratification tools 12 . A key factor in explaining these different results may be the timing of biomarker 197 * Adjusted for age, BMI, history of diabetes or hypertension, systolic blood pressure and pulse, anterior myocardial infarction, and time to treatment. 249 patients were excluded because of missing values. Excluded patients had a higher BMI, Troponin T, NT-pro-BNP, more often history of PCI/CABG and lower systolic blood pressure. BMI = body mass index; CABG = coronary artery bypass grafting. Other abbreviations as in Tables 1 and 2. assessment. In our study, blood samples were obtained prior to PPCI. In the study by Brügger-Andersen et al., blood samples were obtained four to six days after the index event. It is likely that biomarker levels have been influenced by the index MI and treatment. In a community-based cohort of elderly men with or without cardiovascular disease, a multimarker approach substantially improved the prediction of death 13 . In this study, addition of individual biomarkers to established risk factors did not result in an improved prediction of mortality. However, addition of a multimarker significantly increased the prediction of mortality, supporting our rationale of adding a combination of biomarkers to improve risk stratification. Table 4 . Multimarker risk score for mortality.
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Biomarker
Add to score
Low risk [4] [5] [6] Intermediate risk >6
High risk
Abbreviations as in Table 1 .
eGFR, glucose, and NT-pro-BNP
Our data emphasize the importance of renal disease, estimated by GFR, as a risk factor for mortality after MI. An eGFR <60 ml/min was associated with an approximately three-to four-fold higher mortality hazard. Possible mechanisms by which renal dysfunction increase mortality risk are progressive renal decline, a high prevalence of coronary risk factors among patients with chronic kidney disease, and "therapeutic nihilism" 5 . Further research may focus on the effect of reperfusion therapy on renal function, as well as efficacy and safety of cardiovascular medication in these patients. This is particularly important when realizing that renal dysfunction has been an exclusion criterion in the majority of clinical trials.
Numerous studies have identified admission glucose as a predictor of adverse outcomes after acute coronary syndromes 14 . However, uncertainty remains whether glucose is a direct mediator of adverse outcomes or an indicator of greater disease severity. Possible pathophysiological mechanisms that may be responsible for the increased mortality with hyperglycemia are direct detrimental effects on ischemic myocardium, microvascular dysfunction, increased inflammation, a prothrombotic state, and an impaired myocardial glucose utilization 14 . The prothrombotic state with hyperglycemia appears to result from a combination of increased thrombin generation and platelet activation as well as inhibited fibrinolysis 15 . A better understanding of the abovementioned mechanisms could lead to specific intervention in order to improve the prognosis regarding mortality. 
alive (p new (j) -p old (j)) / n (alive)) p=predicted probability of mortality Abbreviations as in Table 1 .
Finally, NT-pro-BNP levels, determined by left ventricular function and extent of myocardial ischemia, has been shown to predict mortality better then established risk factors 2 . Importantly prior MI, being a determinant of left ventricular function, was not included in our adjusted multimarker model. We included prior MI in exploratory analyses to make a fairer evaluation of NT-pro-BNP, and this did not materially alter the hazard ratios. Moreover, BNP has been shown to predict long-term mortality independently of the presence of clinical evidence of heart failure 16 .
cTnT and CRP
Admission cTnT and CRP were not predictive in the multivariable analyses. This may be due in part to redundancy between several biomarkers. Regarding cTnT, a major limitation of this assay is the low sensitivity at admission because of a delayed increase in circulating levels 17 , typically peaking several hours after revascularization. An elevation in CRP levels can be discerned around 16 hours after the onset of symptoms 18 . Complicating the assessment of CRP is the observation that higher admission CRP values are observed in patients with preinfarction unstable angina, compared with those presenting with an unheralded MI 19 . We appreciate that assessment of cTnT and CRP at admission does not fully represent the potential prognostic value provided by later assessments. However, our current model is based on admission data and provides valuable prognostic information at the start of PPCI.
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Multimarker score
Our multimarker score stratified STEMI patients in low-, intermediate-, and high-risk subgroups concerning long-term mortality. Patients were admitted a mean of 2 hours after onset of symptoms. Although biomarkers were measured at a later time point offline in our study, such results could have been available during the PPCI procedure with rapid bed-side tests. The main advantage of this multimarker score is its simplicity and strong discriminative capacity. When confirmed by other independent cohorts 20 , our multimarker score may be useful to identify patients eligible for adjuvant therapies during or after PPCI. This is particularly important in view of the number of new treatments investigated in STEMI such as ticagrelor and delta-protein kinase C inhibitors 21, 22 , potentially leading to resource-limited treatment options.
Finally, the use of coronary intervention, fibrinolytic / antithrombotic therapy and secondary prevention have led to a low mortality after STEMI. This means that very large sized trials would be needed to be adequately powered to show a mortality benefit for promising new adjunctive therapies. Focusing on the high-risk subgroup may assist in designing modest size, but adequately powered trials.
Limitations
Several limitations of the current study deserve mention. First, there is a potential selection bias because of 306 excluded patients with missing or incomplete biomarkers. We assume that this limitation has not significantly influenced our results, because no major differences were observed in baseline characteristics of included and excluded patients. In the adjusted multimarker, 249 patients were excluded because of missing established risk factor data. Second, the single use of data from our PCI center could have caused further selection of patients. Third, the established prognostic factors used in our analyses were derived from the TIMI risk score 1 . Although the TIMI risk score was derived from a clinical trial population instead of a "real world" population, this score has been validated in a community based STEMI population 23 . Finally, information on vital status was obtained from the Dutch national population registry, wherein information on the cause of death is not available.
CONCLUSIONS
Our data suggests that the sole use or addition of a multimarker to a model including established risk factors improves the prediction of mortality in STEMI patients undergoing PPCI. 
